{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021953","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.607129+00:00","generated_at":"2026-06-15T00:50:15.269702+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Larimar Phase 2 trial shows frataxin increases in skin and buccal cells; Q1 net loss $6.5M","bullets":["Median placebo-adjusted frataxin increase from baseline: 3.5 pg/µg in skin, 0.9 pg/µg in buccal cells at day 14.","CTI-1601 generally well tolerated; one severe allergic reaction led to withdrawal; 8 of 9 completed the cohort.","Data submitted to FDA; meeting scheduled Q2 2023; program update expected Q3 2023.","Q1 2023 net loss $6.5M ($0.15/diluted share) vs $8.9M ($0.49) in Q1 2022; cash $111.5M as of March 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021953","json":"https://secwatch.observer/filing/0000950170-23-021953.json","markdown":"https://secwatch.observer/filing/0000950170-23-021953.md","text":"https://secwatch.observer/filing/0000950170-23-021953.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000095017023021953/0000950170-23-021953-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000095017023021953/lrmr-20230515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T00:50:15.269702+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66bd8d605fec47a034d934b45c0dc3214268c66d","claim":"Larimar Therapeutics, Inc. reported financial results for first quarter ended March 31, 2023.","evidence_excerpt":"On May 15, 2023, Larimar Therapeutics, Inc. (the “ Company ”) announced its financial results and operational highlights for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374690/000095017023021953/0000950170-23-021953-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}